Directions: Consume 2-8 capsules daily or as directed by your physician.

Do not use if bottle seal is broken or damaged.

Adjustment of the intestinal flora can take a few days or weeks; it may take up to one month for the colonization of the gut to become optimally stable.

Some dairy ingredients are used in the culture medium but are removed during manufacturing. Product may contain trace amounts of dairy ingredients at very low levels.

Drug Interactions
Avoid taking with antibiotics. Some antibiotics may inactivate certain strains of bacterium in VSL#3.

Side Effects
Mild abdominal bloating has been reported in the first few days of consuming VSL#3.

Precautions
Please keep this product out of reach of children.

Pregnant or lactating women should consult with a physician or healthcare professional before using this or any other medical food product.

Dairy Status
Some dairy ingredients are used in the culture medium but are removed during manufacturing. There might be trace amounts at very low levels. For this reason VSL#3 is not defined as a dairy-free product but as a non-dairy product.

Storage
VSL#3 Capsules should be refrigerated (39-46(0)F, 4-8(0)C). If stored under refrigeration, the product is guaranteed through “Best if used by” date. VSL#3 Capsules can be stored at room temperature for up to one week without adversely affecting potency of bacteria.

Gluten Status
VSL#3 is gluten-free

Description: VSL#3 capsules are a medical food which is intended for the dietary management of irritable bowel syndrome (IBS) and ulcerative colitis (UC). VSL#3 is a probiotic consisting of 8 strains of live freeze-dried lactic acid bacteria.

VSL#3 and The Living Shield are trademarks of VSL Pharmaceuticals, Inc. US Patent # US RE 40,023E and other Patents Pending.
2012.

As a medical food VSL#3 is specially formulated and processed to provide a precise mixture of certain bacterial species with potential synergistic relationships.

VSL#3 Capsules are intended for use only by IBS or UC patients under the care of a physician.

Clinical Experience
VSL#3 Capsules (reported as VSL#3) has been the subject of extensive clinical research in the dietary management of IBS or UC. The consumption of VSL#3 has been shown to be effective in the management of gas and bloating associated with IBS in two placebo-controlled randomized trials conducted at the Mayo Clinic.1,2 In one study, the consumption of VSL#3 reduced bloating by 39% in patients with diarrhea-predominant IBS.1 In the same study, fecal urgency scores showed a trend toward reduction vs placebo. In a second study, the consumption of VSL#3 reduced flatulence (gas) by 25% vs placebo.2 In both IBS studies the consumption of VSL#3 was well tolerated with no adverse events reported. In a study evaluating the efficacy of VSL#3 consumption in UC patients intolerant or allergic to 5-ASA, 75% of patients maintained remission for 12 months.5